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ABSTRACT 
Endometriosis is a chronic inflammatory disease where there is growth of endometrial tissue 
in ectopic sites, most commonly within the pelvic cavity. The major symptoms of this disease 
are chronic pelvic pain and infertility. There are both medical and surgical options to treat 
endometriosis, however, there is a high recurrence rate of ectopic lesions and symptoms, and 
hence a need for more effective therapies. Although the exact etiology is unclear, the most 
widely accepted theory describing the origin of endometriosis is Sampson’s theory of 
retrograde menstruation. This theory states that during menstruation there is retrograde 
movement of endometrial tissue back into the pelvic cavity that grows to become ectopic 
endometrial tissue through its increased ability to survive, proliferate, migrate, adhere, invade, 
and promote angiogenesis to support its growth. However, only approximately 10% of women 
of reproductive age develop endometriosis, while almost all women exhibit retrograde 
menstruation. Therefore, other mechanisms have been suggested to be involved in the 
development of endometriosis such as reduced immunosurveillance in the pelvic cavity 
through modulation or aberrant responses of immune cells such as macrophages and natural 
killer (NK) cells, and involvement of stem/stromal cells such as mesenchymal stromal cells 
(MSC).  
In endometriosis it is known that there is a predominance of immunosuppressive M2 
macrophages, and inhibition of function of NK cells in the pelvic cavity. Both immune cell 
types have been suggested to contribute to the reduced immunosurvelliance of ectopic 
endometrial tissue. However, the exact cause of this reduced immunosurveillance is currently 
unknown. MSC are multipotent cells found in various tissue sources as well as in ectopic 
endometrial and eutopic endometrial tissue. Their immunomodulatory abilities have been 
utilized as a treatment in immune mediated diseases through their immunosuppressive effects 
on immune cells such as macrophages and NK cells. Interestingly, MSC have been suggested 
to exist as MSC1 (an immunostimulatory phenotype), or as MSC2 (an immunosuppressive 
phenotype), with the latter phenotype being the most commonly investigated in the literature 
(see Table 1).  
Therefore, herein it was hypothesized that MSC derived from endometriotic ovarian cysts 
could be involved in the reduced immunosurveillance of ectopic endometrial tissue in the 
pelvic cavity through their immunosuppressive effects on macrophages and NK cells. 
Moreover, if autologous MSC are involved in the pathology, then it was hypothesized that the 
immunomodulatory capabilities of allogeneic MSC could be a potential therapeutic strategy to 
target the inflammatory component of endometriosis.  
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Study 1 was an in vitro study that found that stromal cells isolated from endometriotic ovarian 
cysts (ESCcyst) of women with endometriosis are more immunosuppressive than stromal cells 
isolated from the endometrium (ESCendo) of women with endometriosis. The ESC were also 
confirmed to be MSC; they expressed MSC markers such as CD73, CD90, and CD105, formed 
colonies when seeded at low densities, and differentiated into osteoblasts and adipocytes. 
ESCcyst expressed significantly higher levels of the immunosuppressive enzymes indoleamine 
2,3-dioxygenase 1, cyclooxygenase 2, and hemeoxygnase 1, and promoted differentiation of 
the more immunosuppressive M2 macrophages. Based on the results of this study we used 
allogeneic adipose tissue-derived MSC (Ad-MSC) in Study 2 to examine their effects on 
ESCcyst and ESCendo in vitro, as a first step of a long-term goal of developing a potential therapy 
for endometriosis. We found that culture with allogeneic Ad-MSC either maintained or 
promoted the proliferation, survival, adhesion, migration and invasion of ESCcyst. Moreover, 
conditioned medium (CM) derived from Ad-MSC and ESCcyst co-cultures promoted tube 
formation of human umbilical vein endothelial cells; tube formation is an in vitro model of 
angiogenesis. In Study 3, the interactions between ESCcyst and NK cells in vitro were 
examined. It was found that following culture in the CM of ESCcyst or in direct co-culture with 
ESCcyst, the phenotype, degranulation, and cytotoxic functions of NK cells were similar to the 
NK cells cultured with ESCendo; the expression of activation, inhibitory, adhesion, and 
maturation receptors was similar, and the level of the degranulation marker CD107a and 
expression of the immunostimulatory cytokine interferon gamma was similar.  
In conclusion, the findings presented in this thesis suggest that immunosuppressive ESCcyst 
may indirectly promote the growth of ectopic endometrial tissue through their inhibitory effects 
on the immunosurveillance in the pelvic cavity through their effects on macrophages but not 
on NK cells. In addition, autologous ectopic MSC such as ESCcyst may be involved in the 
pathogenesis of endometriosis through their direct growth promoting effects on ectopic 
endometrial tissue.  
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1 INTRODUCTION 
1.1 ENDOMETRIOSIS  
1.1.1 Background  
Endometriosis is an estrogen dependent and chronic inflammatory disease defined by the 
presence of ectopic endometrial tissue, with the pelvic cavity being the most common site (1). 
Occasionally ectopic lesions may be found in other regions of the body such as the lungs, 
kidney, and brain (1). Although endometriosis may have systemic effects (2), it is largely seen 
as a local disease within the pelvic cavity. Laparoscopy is the gold standard for conclusive 
diagnosis of endometriosis, preferably along with histological confirmation of endometrial 
glands and stroma in the ectopic lesions (3, 4). Globally, approximately 10% of women of 
reproductive age suffer from endometriosis, which represents a great number (1). Moreover, 
around 35-50% of women with chronic pelvic pain and/or infertility have endometriosis (4) 
The symptoms of endometriosis can be devastating and include dysmenorrhea and 
dyspareunia, with the two major symptoms being chronic pelvic pain and infertility (1). The 
total annual healthcare costs of endometriosis are considerable. In the United States alone, 
endometriosis related spending was estimated to be around $69.4 billion in 2010 following a 
multicenter prospective study, with these costs being mainly due to a loss of productivity of 
affected individuals (5).  
1.1.2 Etiology  
The etiology of endometriosis remains unknown, with Sampson’s theory of retrograde 
menstruation being the most widely accepted for describing the origin of endometriosis (6). 
This theory states that retrograde flow of endometrial tissue via the fallopian tubes into the 
pelvic cavity during menstruation leads to the occurrence of endometriosis (6). However, this 
theory alone is insufficient in explaining the pathology of endometriosis since almost all 
women of reproductive age exhibit retrograde menstruation, but not all develop the disease (6). 
Therefore, other factors appear to be important in the development and progression of 
endometriosis, and other theories may further explain the pathogenesis of endometriosis. There 
is a theory that suggests that ectopic lesions originate from epithelial-like and/or stromal like 
stem cells, which are refluxed back into the pelvic cavity through retrograde menstruation 
supporting a stem cell theory for the pathogenesis of endometriosis (7). For example, several 
studies have demonstrated that ectopic lesions are monoclonal in origin, and mesenchymal 
stromal cells (MSC) have been found to exist in menstrual blood, which may carry them to the 
pelvic cavity during retrograde menstruation (8-11). Additionally, the stem cells may also 
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originate from the bone marrow, with this being supported by findings that show stem cells 
engraft in the endometrium via an estradiol regulated C-X-C motif chemokine (CXCL) 12 - C-
X-C chemokine receptor type 4 axis. (12-14). Another theory suggests that the epithelial lining 
of the ovaries and peritoneum may undergo metaplasia, and then transform into endometrium 
leading to endometriosis (15). Yet another theory suggests that the remaining cells from the 
mullerian ducts that migrate during embryo development retain the ability to form ectopic 
lesions when exposed to estrogen during adolescents (1). Autoimmune disease also tends to be 
more common in patients with endometriosis. This supports the concept that endometriosis 
may develop due to a defective immune system, preventing the removal of ectopic lesions and 
consequently allowing the growth of ectopic endometrial tissue (15).  Natural killer (NK) cells 
are one of the immune cells that are recruited to the pelvic cavity, however, their functions have 
been found to be inhibited (16, 17). Another component related to a defective immune system, 
and that may partly explain the etiology of endometriosis are the macrophages, which are 
abundant in ectopic lesions in endometriosis (18).  
1.2 MACROPHAGES AND ENDOMETRIOSIS 
1.2.1 Background  
Macrophages are the major leukocyte recruited to ectopic endometriotic lesions (19), where 
they undergo polarization into M2 macrophages (18). Moreover, the pelvic cavity contains 
resident macrophage that may also be involved in the pathology of endometriosis (20). 
Macrophages are innate immune cells derived from monocytes that play a crucial role in the 
innate immune response (21). Depending on the signals in their microenvironment, monocytes 
have been found to be able to differentiate into the M1 macrophages or the M2 macrophages 
(21) and Table 1. For example, interferon gamma (IFN-γ), tumor necrosis factor-α (TNF-α), 
and granulocyte macrophage colony stimulating factor induce development into M1 
macrophages, while interleukin 4 (IL-4) and IL-13 induce development into M2 macrophages 
(22, 23). M1 and M2 macrophages have distinctly different properties. M1 macrophages are 
associated with expression of high levels of pro-inflammatory cytokines such as IL12 and IL13, 
and promotion of T helper (TH) 1 responses (21) (Table 1). Moreover, phenotypically M1 
macrophages display low expression of CD14, CD163, CD204, CD206, and B7H4 and 
increased expression of CD11b (24) (Table 1). In contrast, M2 macrophages are associated 
with a higher expression of CD163, CD204, CD206, CD209, and B7H4, and decreased 
expression of human leukocyte antigen (HLA)-DR and CD11c (19, 24) (Table 1). M2 
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factor-beta 1 (TGF-β1) that allow them to inhibit the responses of other immune cells (19, 21) 
(Table 1). It has been suggested that M2 macrophages have subtypes: M2a, M2b, and M2c, 
however, their exact phenotypes and functions are still not completely known (25).  
Activation of macrophages plays a key role in the pathology of various inflammatory diseases 
such as atherosclerosis, inflammatory bowel disease, and rheumatoid arthritis (26, 27). 
Likewise, in endometriosis various studies show the presence of M2 macrophages in the local 
environment of the pelvic cavity, and that these cells may play a crucial role in the initiation 
and progression of endometriosis (28-30).  
1.2.2 Macrophages in Endometriosis 
In endometriosis, macrophages have been found to be recruited to ectopic lesions where they 
have been suggested to be involved in meditating their growth (31-34). Initially, recruited 
macrophages secrete factors like cytokines, and phagocytose red blood cells, and other cellular 
and tissue fragments to help prevent or control the growth of ectopic lesions, and to shape 
impending adaptive immune responses (35). However, it seems that as the disease progresses, 
their functions are altered and they become involved in the progression of the disease (36, 37). 
The signals that lead to their recruitment and activation are still unknown, however, it may be 
due to local hypoxia in the pelvic cavity, the iron overload as a consequence of dying 
erythrocytes derived from retrograde menstruation, or from unknown signals (38-40). The 
following is a discussion regarding current knowledge about macrophages in endometriosis. 
Studies in both mice and rat models of endometriosis found that when macrophages were 
depleted this hindered the initiation and development of endometriosis (28, 41). It has been 
found that macrophages are needed to deliver trophic and anti-apoptotic signals that induce 
angiogenesis, survival, and growth of ectopic cells in the hostile hypoxic environment of the 
pelvic cavity (42-45). This hypothesis is supported by another study that found that the ectopic 
endometrium expresses the macrophage-colony stimulating factor receptor (M-CSFR), which 
allows the endometrium to survive and proliferate when stimulated by M-CSF secreted by 
peritoneal macrophages (46). Moreover, macrophages in mice and also in women with 
endometriosis have been found to express high levels of CD163 and CD206, an indication of 
M2 macrophage polarization (28). They suggested that the signals that promoted the 
differentiation of monocytes into the reparative M2 macrophage phenotype likely existed in 
the local microenvironment (28). One such signal could be M-CSF, which is known to be able 
to induce monocyte differentiation into M2 macrophages, and has been found to be at a higher 
concentration in women with endometriosis than in women without endometriosis (47, 48). 
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These findings complement what is known about macrophages derived from endometriotic 
lesions, in that they are involved in clearing dying erythrocytes and endometrial cell debris via 
phagocytosis, and secreting trophic and angiogenic molecules (40, 49). To test the hypothesis 
that M2 macrophages play a crucial role in endometriosis development, M1 or M2 
macrophages were adoptively transferred into mice following disease establishment (28). 
Interestingly, M1 macrophages disrupted, while M2 macrophages promoted endometriotic 
lesion development, respectively (28). The results of these studies demonstrate that it may be 
possible to treat endometriosis by inhibiting the functions of M2 macrophages in the pelvic 
cavity.  
RANTES (C-C chemokine, regulated on activation, normal T cell expressed and secreted), a 
pro-inflammatory cytokine present in the ectopic milieu of endometriosis, was found to induce 
macrophage recruitment and tolerance (50). These recruited tolerant macrophages displayed 
characteristics of M2 macrophage with increased expression of CD14 and IL-10, but decreased 
expression of HLA-DR (50). In turn, these macrophages were found to inhibit apoptosis of 
stromal cells derived from the eutopic endometrium of women with endometriosis (ESCendo) 
(50). Therefore, the authors concluded that the high levels of RANTES in the peritoneal cavity 
induces tolerance of macrophages, which promote the survival and growth of ectopic lesions 
(50). Matrix metalloproteinases (MMP) are endopeptidases that possess the capacity to cleave 
all components of the extracellular matrix when activated (29). Additionally, they are capable 
of regulating cell proliferation, survival, migration and angiogenesis, and therefore, their 
overexpression can contribute to the pathogenesis of endometriosis (29). A study found that 
MMP27 was specifically expressed in M2 macrophages from endometriotic lesions, and this 
may contribute to disease progression by favoring survival and growth of ectopic lesions (29). 
Another study indirectly demonstrated that M2 macrophages are induced in the pelvic cavity 
by finding that IL1β, an inflammatory cytokine associated with endometriosis, upregulated the 
expression of thymic stromal lymphopoietin (TSLP) by stromal cells derived from the 
endometriotic ovarian cysts of women with endometriosis (ESCcyst), which is a master cytokine 
that drives the TH2 response (51). This complemented their findings that TSLP is found at high 
levels in the peritoneal fluid of women with endometriosis, and so they suggested that TSLP 
secretion from ESCcyst may promote the disease via the TH2 response and subsequent induction 
of M2 macrophages (51). Another study by Nie et al. found that ESCendo-derived conditioned 
medium (CM) induced by IL-6 promoted more polarization of M2 macrophages derived from 
THP-1 cells (human monocyte leukemia cell line) than ESCendo-derived CM not induced by 
IL-6 (52). They suggested that IL-6 present in the pelvic cavity of women with endometriosis 
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may be involved in M2 macrophage induction (52). The aforementioned studies are indirect 
evidence that stromal cells may be promoting M2 macrophages in endometriosis. 
It is generally known that TH2 responses induce polarization of macrophages towards the M2 
phenotype (53, 54). For example, cytokines such as IL-4 and IL13 that are associated with a 
TH2 response are known to drive monocytes towards the M2 phenotype (55). Interestingly, 
several studies have found that endometriosis is associated with a reduced TH1 immune 
response, and an increased TH2 response that may allow the survival, implantation, and 
proliferation of ectopic lesions through activation of M2 macrophages (51, 56-59). One study 
found that administration of TH1 but not TH2 cytokines inhibited the growth of ectopic lesions 
in a mouse model of endometriosis. This was suggested to be due to the activation of M1 
macrophages, and the cytotoxic effector functions of CD8+ T cells and NK cells (59).  
Therefore, the pelvic cavity in endometriosis seems to contain various factors along with 
stromal cells that are synergistically pushing macrophages towards the M2 phenotype, which 
seems to be promoting endometriosis development. However, the exact mechanisms by which 
M2 macrophages are induced in pelvic cavity in endometriosis are unknown. Studies on the 
interactions of stromal cells and macrophages are discussed later.  
1.3 NATURAL KILLER CELLS AND ENDOMETRIOSIS  
1.3.1 Background 
Just like macrophages, NK cells are also part of the innate immune system, and have also been 
found to be activated and recruited to ectopic endometriotic lesions early on during the disease 
(60). Several chemokines are found at high levels in the pelvic cavity, including CXCL12 
which is involved in NK cell recruitment; this is not surprising since the levels of chemokines 
are regulated by estrogen that is known to be increased in endometriosis (61). The normal 
function of NK cells is to secrete cytokines and to target cells for destruction, both of which 
help them carry out their cytotoxic activities, and to determine the type of impending responses 
produced from the adaptive immune system (60). NK cells are a type of lymphocyte, however, 
unlike the other lymphocytes T cells and B cells of the adaptive immune system, NK cells have 
the innate ability to distinguish abnormal cells from normal cells, and then to target them for 
destruction without any requirement for antigen presentation by antigen presenting cells (61). 
Although they are not completely clear, the mechanisms by which NK cells carry out their 
cytotoxic functions are thought to be through a detection system involving a wide range of cell 
surface activating receptors such as NKG2D and inhibitory receptors such as NKG2A (61). In 
addition, killer immunoglobulin-like receptors (KIRs) found on the surface of NK cells are 
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involved in the recognition of HLA molecules on target cells, and the regulation of NK cell 
cytotoxicity (2). Whether activating or inhibitory receptors predominate on the surface of NK 
cells depends on the corresponding induced NK cell stress ligands on target cells, presence of 
HLA proteins on target cells, and the presence of cytokines in their microenvironment, such as 
IL-2 that is known to activate NK cells (61). Transformed cells may lose their expression of 
HLA proteins leading to missing-self and the subsequent activation of the NK cells (61). 
Moreover, stressed cells may upregulate stress ligands such as HLA-E that may engage and 
activate activation receptors on the surface of the NK cells (61). Activation of NK cells leads 
to their degranulation and release of granules containing molecules such as the cytolytic protein 
perforin and the serine protease granzyme b that perforate the membranes of target cells and 
induce their apoptosis, respectively (62).  
Two types of NK cells are able to be distinguished based on their expression of the cell surface 
markers CD56 and CD16 (63). CD56dim NK cells are more cytotoxic due to their high level of 
expression of CD16, while CD56bright NK cells are less cytotoxic due to their low level of 
expression of CD16, but secrete high levels of cytokines such as IFN-γ, and hence are involved 
in immune regulation (63). Most of the NK cells present in the peripheral blood are of the 
former type, while most of the NK cells in the endometrium are of the latter type (61). More 
recently, resident NK cells in the pelvic cavity have been characterized (64), which along with 
the recruited NK cells, may be involved in the pathogenesis of endometriosis. 
1.3.2 Natural Killer Cells in Endometriosis 
It is known that NK cells are recruited to ectopic lesions in endometriosis, but it has been found 
that the number of cytotoxic NK cells is reduced, the number of immature NK cells is increased, 
and their phenotype, and hence function is inhibited (2, 16, 17, 65-68). The levels of various 
molecules important in the cytotoxicity of NK cells such as granzyme b, perforin, TNF-related 
apoptosis-inducing ligand, and the degranulation marker CD107a are all reduced in the 
peritoneal fluid, and the levels of receptors important in NK cell activation such as NKp46, 
NKp44, NKG2D, CD16, and CD69 on peritoneal NK cells are also reduced in women with 
endometriosis; indicating that NK cell function is inhibited in endometriosis (2). The following 
is a discussion regarding current knowledge about NK cells in endometriosis. 
Interestingly, a study examining the phenotype of ectopic endometrial cells found that their 
expression of HLA-G, which is a ligand of the KIR2DL4, prevented their detection by NK 
cells and allowed their survival and growth (69). Liu et al. found that NK cells from the 
peritoneal fluid of women with endometriosis that expressed the immunosuppressive enzyme 
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indoleamine 2,3-dioxygenase (IDO) 1 expressed lower levels of the activation receptors 
NKp46 and NKG2D and secreted more of the immunosuppressive cytokine IL-10, and hence 
were more inhibited compared to IDO1 negative NK cells  (68). Oosterlynck et al. found that 
NK cells from women with endometriosis have reduced cytotoxicity against the K562 cell line 
and autologous ESCendo compared to NK cells from women without endometriosis in 
chromium 51 (51Cr) release assays (16, 17). A similar study found that NK cells from women 
with endometriosis have reduced cytotoxicity against the K562 cell line in 51Cr release assays 
compared to women without endometriosis, and suggested that it could be due to their 
increased expression of KIRs (70). KIRs have also been found to be more highly expressed on 
NK cells from women with endometriosis compared to women without endometriosis in 
several other studies (71-73). The NKG2D receptor is known to be a potent activator of NK 
cells that it has the potential to override inhibitory signals mediated by inhibitory receptors 
(74). Interestingly, a study found that TGF-β1 derived from platelets isolated from the 
peritoneal fluid of women with endometriosis can reduce the expression of the NKG2D 
receptor, and may be involved in the reduced cytotoxicity of NK cells from women with 
endometriosis (74). Another study related to the NKG2D receptor, found that soluble ligands 
for the NKG2D receptor were increased in the pelvic cavity in women with endometriosis, 
which act as decoy receptors and may allow evasion of ectopic cells from NK cells (75). It was 
also found that peritoneal fluid-derived NK cells expressing the activating NKp46 receptor 
were reduced in number in women with endometriosis compared to women without 
endometriosis (76). Furthermore, a study found that CD94/NKG2A+ peritoneal NK cells were 
increased in women with endometriosis compared to women without endometriosis (77); this 
is an inhibitory NK cell receptor that interacts with the nonclassical molecule HLA-E that has 
also been found to be abundant on ectopic and eutopic cells from women with endometriosis 
(78).  
Similar to a pervious study (79), Kang et al. found that the peritoneal fluid from women with 
endometriosis reduced the differentiation and cytotoxicity of NK cells compared to the 
peritoneal fluid from women without endometriosis (65). They attributed this finding to the 
increased levels of IL-6 in the peritoneal fluid of women with endometriosis, which they found 
to be negatively correlated with the cytotoxicity of NK cells (65). IL-6 is a pleiotropic molecule 
that is able to modulate various aspects of NK cell cytotoxicity (2). Furthermore, it was found 
that the levels of the Fas ligand (80, 81) are increased in the peritoneal fluid of women with 
endometriosis, and peritoneal NK cells in women with endometriosis expressed elevated levels 
of the Fas receptor (82), suggesting that NK cells may actually undergo Fas ligand induced 
apoptosis allowing immune escape of ectopic cells. 
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It is clear that there are various mechanisms at play leading to the eventual dysfunction of NK 
cells in women with endometriosis. However, the exact mechanisms by which the functions of 
the NK cells are inhibited are not currently known, but the aforementioned studies suggest that 
certain factors present in the pelvic cavity due to inflammatory changes in the 
microenvironment, and epithelial and stromal cells may be involved. Studies on the interactions 
of stromal cells and NK cells are discussed later. 
1.4 THERAPIES FOR ENDOMETRIOSIS 
There are various medical and surgical treatments for women with endometriosis but treatment 
failure is frequent and no definite cure is available (83). The initial treatment of a patient with 
endometriosis depends on the severity of her symptoms and her desire for fertility (83). Pain, 
the most common symptom of endometriosis, is thought to be due to a consequence of pro-
inflammatory cytokines in the peritoneal cavity, bleeding from ectopic lesions, and invasion 
and irritation of pelvic floor nerves by the ectopic lesions (83). Around 25-50% of infertile 
women suffer from endometriosis, suggesting that endometriosis causes infertility, even 
though a clear causal relationship remains to be demonstrated (83, 84). Disturbed ovum 
transport may be due to distorted pelvic anatomy and chronic inflammation, which may also 
cause infertility due to reduced receptivity of the uterus, reduced folliculogenesis of the ovaries, 
and abnormal function of the uterine tubes (83). In infertile women with endometriosis, surgery 
and assisted reproductive technologies such as superovulation and intrauterine insemination, 
and in vitro fertilization may be considered. There is no evidence that medical therapies can 
help to improve fertility (83). In fact, medical therapies can delay the ability of a woman to 
conceive, because they can minimize the effects of the biological processes that are required to 
allow and maintain a pregnancy (7). However, if fertility is not desired and containment of pain 
is the only goal, then both medical and surgical treatment options are utilized (83).  
Based on the retrograde menstruation theory, and the fact that ectopic lesions behave in a 
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amenorrhea and reducing growth of the ectopic lesions (85, 86). Therefore, medical therapies 
are used to inhibit ovulation and menses to reduce inflammation, and the effect of estradiol, 
and other hormones from the ovaries (87). Medical therapies are predominantly symptomatic 
and not cytoreductive, and include combined oral contraceptives (COCs), progestogens only 
contraceptives, and gonadotropin-releasing hormone (GnRH) agonists and antagonists (88). 
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studies, but there is not enough evidence to support their clinical use or they are yet to be tested 
clinically (88). 
The first line of treatment for the pain associated with endometriosis is normally COCs due to 
their low cost and their long term usability (83). Moreover, another first line treatment are the 
nonsteroidal anti-inflammatory drugs (NSAIDs), however, evidence demonstrating their 
effectiveness in reducing the pain associated with endometriosis remains inconclusive (89). 
Cyclooxygenase 2 (COX2) and prostaglandins are highly expressed in endometriosis and seem 
to mediate the endometriosis-associated pain, and both are blocked by NSAIDs (88). In 
contrast, COCs, which are either used cyclically or continuously, function by inhibiting the 
endogenous production of estrogen by a negative feedback mechanism, leading to a reduction 
in prostaglandins and inflammation (88). Moreover, COCs may be inducing a 
pseudopregnancy state by causing decidualization and atrophy of the endometrium (90).  
COCs are contraindicated in women with certain co-existing medical disorders. In this case, 
most women can instead be treated with progestogens only, which can be considered as a 
second line of treatment for endometriosis-associated pain (83). Progestogens mediate their 
effects by suppressing endometrial estrogen receptors, leading to decidualization, and eventual 
atrophy of endometrial tissue (90). Moreover, the suppression of MMP in the endometrium by 
progesterone may also be contributing to their beneficial effects (90). The side effects of 
progestogens that include irregular bleeding, weight gain, bloating, fluid retention, breast 
tenderness, headaches, nausea, and mood changes can limit their use, nevertheless, the reduced 
bone mineral density loss compared GnRH agonists, make them an attractive option for certain 
women requiring treatment for their endometriosis-associated pain (91, 92). 
When COCs and progestogens cannot be used or when they are contraindicated, or when there 
is a failure of therapy, GnRH agonists may be considered as a third line of treatment (88). 
GnRH agonists are modified versions of the native GnRH, which allow them to bind to their 
receptors for a longer period of time leading to nonpulsatile signaling (83). This causes a 
hypogonadotrophic and hypoestrogenic state, which leads to amenorrhea and endometrial 
atrophy (90, 93). However, this hypoestrogenic state leads to bone mineral depletion and 
vasomotor symptoms, limiting their long term use (93). Due to this, an ‘add back’ therapy 
utilizing estrogen and progestogen, or estrogen alone is used, which has demonstrated an 
effectiveness in counteracting the side effects as well as simultaneously controlling the 
endometriosis-associated pain (90, 93-95). 
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Not all women respond favorably to medical treatments for endometriosis pain and may require 
surgical treatment (83). The goals of surgery are to help reduce endometriosis-associated pain 
by removing ectopic lesions, to restore normal anatomy, and reduce the risk of disease 
recurrence (83). Surgery may involve ablation, excision or drainage of endometriotic cysts, 
lysis of adhesions, and destruction of peritoneal implants (87). However, there is a high 
recurrence rate of ectopic lesions due to microscopic endometriosis lesions that are difficult to 
remove surgically, and whose removal depend highly on the surgical skills of the surgeon (7). 
Although there are various treatment options for endometriosis, there is a high recurrence rate 
of ectopic lesions and pain symptoms. Moreover, current treatments only target the symptoms 
of endometriosis and are usually not curative. Therefore, there is an urgent need for new and 
more effective therapies that not only target the symptoms caused by endometriosis, but also 
the disease progression. Due to the notion that immunosuppressive MSC may be useful as a 
potential therapy for inflammatory diseases like endometriosis, we carried out Study 2. 
However, along with our findings in Study 2, later in this section it will be discussed how an 
immunosuppressive subtype of MSC may actually instead be involved in the pathogenesis of 
endometriosis.  
1.5 MESENCHYMAL STROMAL CELLS AND ENDOMETRIOSIS 
1.5.1 Background 
MSC are multipotent stromal cells that can be isolated from various tissues such as the bone 
marrow, placenta, endometrium, and umbilical cord, among others (96). The terms 
mesenchymal stromal cells and mesenchymal stem cells are interchangeable and refer to the 
same type of cells. MSC were first described as spindle shaped and fibroblast-like cells derived 
from the bone marrow that were able to form colonies when seeded at low densities (97). The 
huge surge in research involving MSC lead to the establishment of a set of criteria that these 
cells need to fulfil in order to be classified as MSC (98). According to these criteria the cells 
have to be plastic adherent, express a certain repertoire of surface markers such as CD73, 
CD105, and CD90 and be negative for CD45, CD31, CD34, CD14, and HLA-DR, and be able 
to undergo multipotent differentiation into the three mesenchymal lineages of adipocytes, 
osteoblasts, and chondroblasts (98).  
MSC are known to be immunomodulatory in that they are able to sense their microenvironment 
and respond to what they detect by either releasing pro- or anti-inflammatory molecules (99, 
100). It is thought that they are able to do this because they contain a machinery for synthesizing 
and secreting a wide range of cytokines, growth factors, and extracellular vesicles (99, 101). In 
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essence, MSC are a double edge sword that are able to sense and fine tune their surrounding 
microenvironment by secreting their repertoire of molecules to maintain homeostasis (99). Due 
to this ability, MSC have been studied as a therapeutic for a wide range of immune mediated 
diseases such as multiple sclerosis, graft versus host disease (GvHD), and type 1 diabetes, 
among others (99). 
Recent research suggests that MSC display plasticity in a similar way as macrophages and may 
exist as different subtypes. Depending on their microenvironment they have been suggested to 
either develop into the MSC1 or MSC2 subtypes (102). When their surroundings are 
inflammatory (high levels of IFN-γ/TNF-α) they develop to become immunosuppressive 
MSC2, which express and secrete high levels of IDO1, COX2, prostaglandin E2 (PGE2), nitric 
oxide (NO), hepatocyte growth factor (HGF), hemoxygenase 1 (HO-1) and TGF-β1 (103) 
(Table 1). MSC2 induce T regulatory cells (Tregs), suppress T cell responses, and promote an 
immune response towards M2 macrophage polarization (103) (Table 1). Meanwhile, in the 
absence of inflammatory surroundings (low levels of IFN-γ/TNF-α) they develop to become a 
pro-inflammatory MSC1, which express and secrete high levels of macrophage migration 
inhibitory factor (MIF) 1α and 1β, CXCL9, and CXCL10 (Table 1) (104, 105). MSC1 induce 
T cell responses, and promote an immune response towards M1 macrophage polarization 
(Table 1) (104, 105).  
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Table 1. Summary of phenotypic and functional characteristics of M1 and M2 macrophages, 
and MSC1 and MSC2. 
Immunostimulatory Immunosuppressive 
M1 
macrophages 
MSC1 
M2  
macrophages 
MSC2 
Phenotypic 
characteristics 
High levels of 
IL-12, IL-13, 
CD11b 
High levels of 
MIF-1α, MIF-
1β, CXCL9, 
CXCL10 
High levels of 
CD163, CD204, 
CD206, CD209, 
B7-H4, IL-10, 
TGF-β1 
High levels of 
IDO1, COX2, 
PGE2, NO, HGF, 
HO, TGF-β1 
Functional 
characteristics 
 
Promote TH1 
responses 
Promote M1 
macrophages, & 
T cell responses 
Promote TH2 
responses 
Promote M2 
macrophages, 
Tregs & suppress 
T cell responses 
1.5.2 Mesenchymal Stromal Cells in Endometriosis 
Indeed, MSC seem to play a role in endometriosis since they are found in ectopic lesions; as 
mentioned earlier they would be expected to be recruited to ectopic lesions via retrograde 
menstruation. However, the role MSC play in endometriosis is not completely known, and 
therefore it was investigated in this PhD project. MSC have been isolated from menstrual blood, 
eutopic endometrium, and ectopic endometriotic lesions from women with endometriosis (11, 
106-109). Some studies have confirmed they are MSC (106, 107), while other studies have not 
confirmed they are MSC (19, 110), however, herein all the relevant studies of stromal cells 
derived from women with endometriosis will be mentioned. Moreover, some studies only 
report that ectopic stromal cells were used, and it is unclear whether the ectopic stromal cells 
were from endometriotic ovarian cysts, peritoneal endometriotic tissue, or deep infiltrating 
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endometriosis tissue, which are the three types of endometriosis lesions that can form in 
endometriosis (111).  
The gene expression of COX2 and HO-1 were found to be higher in ESCcyst and stromal cells 
from peritoneal endometriotic tissue compared to ESCendo (112, 113). Moreover, ectopic 
stromal cells were found to have a greater protein expression of COX2 and production of PGE2 
compared to ESCendo derived from healthy female volunteers (ESCendohv) (114). In another 
differently designed study, the gene expression of IDO1 and COX2 was found to be higher in 
menstrual blood-derived stromal cells from women with endometriosis compared to menstrual 
blood-derived stromal cells from women without endometriosis after culture in a transwell 
system with peripheral blood mononuclear cells (PBMCs) (11). These studies suggest that 
immunosuppressive MSC2 may be present in endometriosis. Additionally, peritoneal M2 
macrophages from women with endometriosis are known to overexpress both COX2 and have 
increased production of PGE2 (115). Therefore, both immunosuppressive MSC and M2 
macrophages may explain the high levels of PGE2 in the peritoneal cavity, which has been 
found to have significant roles in the survival and growth of ectopic lesions, and unsurprisingly 
has been a pharmacological target in several studies (116-120). Moreover, the high levels of 
PGE2 found in endometriosis has been found to reduce the ability of the peritoneal M2 
macrophages to mediate phagocytosis by inhibiting the expression of annexin A2, MMP9, and 
CD36 (121, 122). Several studies mimicked the in vivo inflammatory environment of the pelvic 
cavity by exposing ESCcyst to pro-inflammatory cytokines such as IL1β, IL17F, and TNF-α in 
vitro, and found that they displayed a significant increase in the gene expression of COX2 and 
production of PGE2 (112, 123, 124). Moreover, exposure of ectopic stromal cells to IL1β in 
vitro induced the gene and protein expression of COX2 and production of PGE2 (114). 
Furthermore, a study generated three-dimensional spheroids using ESCcyst, and found that their 
gene expression of COX2 and production of PGE2 were high, which were then inhibited when 
treated with the progestin dienogest (125).  
As discussed earlier, M2 macrophages seem to play a critical role in the growth of ectopic 
lesions through direct and indirect mechanisms, however, it is not exactly known what is 
promoting this phenotype of macrophages in the pelvic cavity in endometriosis. Several studies 
indirectly suggest that MSC may be promoting M2 macrophages in endometriosis. A study 
found that ESCendo polarized U937 monocytes stimulated with lipopolysaccharide into M2 
macrophages, which showed an increased expression of the immunosuppressive cytokine IL-
10 and a decreased expression of the costimulatory molecule CD86 (30). It was suggested that 
fractaline (FKN) derived from ESCendo drove the M2 polarization of the macrophages (30). 
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Furthermore, another study found that ectopic stromal cells induced M2 polarization of 
macrophages (19). The M2 macrophages showed increased expression of CD163 and CD209, 
and their intracellular expression and extracellular secretion of TGF-β1 and IL-10 were 
increased compared to macrophages treated with ESCendohv (19). They suggested that IDO1 via 
IL-33 secreted by the ectopic stromal cells was driving the M2 macrophage polarization. 
Moreover, the M2 polarized macrophages significantly increased the viability and 
proliferation, and decreased apoptosis of ESC (126), and enhanced the invasiveness of ESCendo 
(30). Endometriotic tissue is known to be highly fibrotic and TGF-β1 is widely known to be a 
key mediator in fibrosis, which has been found to be secreted by both ectopic stromal cells 
(127) and peritoneal macrophages (128). Further supporting the role of MSC in fibrosis, a 
recent study found that MSC in ectopic lesions may be involved in fibrosis development in 
endometriosis via their secretion of TGF-β1 (129). Interestingly, a recent study suggested that 
that M2a macrophages may play an important role in fibrosis in mice with endometriosis (130). 
Individual to individual variations in terms of the immunological microenvironment and 
endocrine factors may occur with the use of ESCendohv as a control in some of the studies 
mentioned. Moreover, stimulating stromal cells with pro-inflammatory cytokines in vitro may 
not reflect the stromal cells in the in vivo microenvironment closely. However, taken together 
the aforementioned studies indirectly suggest that MSC2 may exist in ectopic lesions, which is 
known to induce the M2 macrophage phenotype that seems to play a significant role in the 
initiation and progression of ectopic lesions in endometriosis; this has been directly confirmed 
by our findings in Study 1.  
As mentioned earlier, NK cells also seem to be playing a role in the growth of ectopic lesions 
through indirect mechanisms, however, it is not exactly known why the function of NK cells 
is inhibited, but stromal cells have been implicated. Liu et al. cultured NK cells from the 
peripheral blood of healthy female volunteers with ESCendohv and ectopic ESC; they found that 
the NK cells enhanced their expression of IDO1, especially following culture with ectopic ESC, 
and the effect was partly due to ESC-derived TGF-β1 (68). Moreover, when the NK cells were 
in turn cultured with ectopic ESC, their cytotoxicity was inhibited, and this was attributed to 
their expression of IDO1 (68). However, as mentioned earlier comparing the effects of ectopic 
ESC to ESCendohv on NK cells is not appropriate, because ESCendohv may introduce individual 
to individual variations in terms of the immunological microenvironment, and endocrine 
factors. Somigliana et al. carried out a study where they observed the effect of supernatant 
released from ESCendohv on NK cell cytotoxicity using ESCendohv as target cells in 
51Cr release 
assays (131). They found that NK cell cytotoxicity was inhibited, and attributed this finding to 
soluble intercellular adhesion molecule 1 that may allow the escape of target cells from NK 
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cell killing (131). Moreover, the same group compared the effects of supernatants released from 
ESCendo and ESCendohv on NK cell cytotoxicity using ESCendohv as target cells in 
51Cr release 
assays, and found that NK cell cytotoxicity was significantly inhibited by supernatants released 
from ESCendo compared to ESCendohv (132). Yu et al. directly co-cultured NK cells from the 
peripheral blood of healthy female volunteers with ESCcyst and ESC from other types of ectopic 
tissue in the presence of IL-15, and compared the results to NK cells cultured alone (133). They 
found that IFN-γ, NKG2D, and NKp44 expression by the NK cells were reduced, and 
concluded that ESC suppress the cytotoxic functions of NK cells to allow their immune escape 
and subsequent growth in endometriosis (133). The same group carried out a study using a 
system that had ESCcyst and macrophages directly co-cultured with NK cells isolated from the 
peripheral blood of healthy female volunteers, and compared the results to NK cells cultured 
alone (60). They found that NK cell cytotoxicity was reduced, and by using blocking studies 
they determined that it may be due to the secretion of both of the immunosuppressive molecules 
TGF-β1 and IL-10 from both ESCcyst and the macrophages (60). However, it seems that the 
effect on the NK cells is mostly due to the macrophages and not ESCcyst (60). Moreover, a 
comparison to ESCendo cultured with the NK cells would be more relevant to the pathology of 
endometriosis. Therefore, various factors, including stromal cells in the pelvic cavity in 
endometriosis seem to be involved in the inhibition of NK function. However, it is not 
completely clear how NK cells are inhibited in the pelvic cavity, therefore, in Study 3 we 
investigated if immunosuppressive ectopic MSC are involved. 
Since endometriosis is widely known to be an inflammatory disease with high levels of pro-
inflammatory cytokines such as IL-6, IL-8, TNF-α, IFN-γ, and IL1β in the peritoneal cavity, 
the findings of the aforementioned studies may not be surprising (103, 134). One could 
speculate that immunosuppressive MSC2 may be induced in order to oppose the high levels of 
inflammation in their surroundings and attempt to return it to homeostasis by inducing various 
immunosuppressive pathways. However, this may be the trigger leading to the initiation and 
progression of this disease by suppressing the immune system from clearing the ectopic lesions.  
1.6 MSC2 AND M2 MACROPHAGES IN ENDOMETRIOSIS  
The Sampson theory of retrograde menstruation is the most widely accepted theory for 
explaining the pathogenesis of endometriosis. In addition, the aforementioned studies support 
the stem cell theory for the pathogenesis of endometriosis (135). The stem cell theory postulates 
that a putative stem/stromal cell population such as MSC are refluxed back into the peritoneal 
cavity via retrograde menstruation, which then give rise to and support ectopic lesions (135, 
136). 
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Consequently, one can speculate that endometriosis is caused by a cascade of events involving 
MSC2 and M2 macrophages as important players initiating and supporting ectopic tissue 
growth (Figure 1). Menstruation is essentially an inflammatory process, so when the menstrual 
fluid containing MSC is refluxed back into the peritoneal cavity during retrograde menstruation 
it leads to an inflammatory environment in the peritoneal cavity (6). This inflammatory 
environment, containing inflammatory cytokines such as IFN-γ and TNF-α, may induce MSC2 
that attempts to oppose the high levels of inflammation in the environment by inducing 
immunosuppressive pathways (137). Then, when innate immune cells such as monocytes are 
recruited, they are modulated by factors such as IDO1, PGE2, and TGF-β1 secreted by MSC2 
to differentiate into M2 macrophages. The M2 macrophages perceive the ectopic endometrial 
tissue as a wound, and release various anti-apoptotic, trophic, and angiogenic factors that 
support the survival and growth of MSC2 and the ectopic endometrial tissue. In addition, based 
on our findings in Study 2, MSC2 may directly support the survival and growth of ectopic 
endometrial tissue. Therefore, although MSC2-induced M2 differentiation of macrophages 
may allow disease amelioration for other conditions, in the case of endometriosis it may instead 
be promoting disease progression (137).  
If retrograde menstruation occurs in almost all women, then why do only approximately 10% 
develop endometriosis? It is well documented that the eutopic endometrial tissue from women 
with endometriosis differs from women without endometriosis in that it has resistance to 
apoptosis, increased migration, increased adherence to the methothelium lining of the 
peritoneal cavity, invasion, and induction of angiogenesis to help it receive nutrients that allows 
its growth (138). It could be speculated that in women not suffering from endometriosis, the 
endometrial tissue may be dying by apoptosis and not persisting. In contrast, the endometrial 
tissue from women with endometriosis may persist and is supported by the M2 macrophages 
to aggressively expand. Moreover, factors released by M2 macrophages and MSC2 such as 
IDO1, PGE2, M-CSF, IL-10, and TGF-β1 may induce TH2 responses, and continue inducing 
differentiation towards M2 macrophages, and subsequently inhibit the functions of 
downstream immune cells such as NK cells, dendritic cells (DC), cytotoxic CD8+ T cells but 
induce the functions of Tregs. There are reports that DC maturation is reduced in endometriosis 
with components of the process of antigen capture and presentation altered; there are increased 
numbers of immature CD1+ DC and reduced numbers of mature CD83+ DC (139, 140). 
Moreover, it has been shown that peripheral, and peritoneal NK cells have impaired cytotoxic 
functions in endometriosis, which may promote the implantation and growth of ectopic lesions 
in endometriosis (65, 69, 77). The cytotoxic functions of CD8+ T cells are also reduced in 
endometriosis (141). Moreover, several studies show that there is an upregulation in the number 
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and functions of Tregs in the ectopic milieu, which may contribute to endometriotic tissue 
immunotolerance and progression of endometriosis (142, 143). 
Further supporting the aforementioned are the wide range of conventional studies that 
demonstrate that MSC are able to induce M2 macrophages, inhibit maturation of DC, reduce 
proliferation and cytotoxic functions of NK cells, and of CD8+ T cells but instead induce 
functions of Tregs (24, 144-148). These functions of MSC may be useful in the treatment of 
inflammatory diseases such as multiple sclerosis, type 1 diabetes, and GvHD, among others 
(99). However, in the case of endometriosis it may be the complete opposite, in that MSC leads 
to a disturbance in the surveillance activities of the immune system in the pelvic cavity, and 
hence allow the survival and growth of ectopic lesions. Therefore, it is unsurprising that a recent 
study suggested that a disruption of the stem cell recruitment to ectopic lesions may allow their 
long-term regression and potentially treat endometriosis (149). 
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Figure 1. Potential role of MSC2 and M2 macrophages in the pathogenesis of endometriosis. 
An illustration of the possible cascade of events involving MSC2 and M2 macrophages in the 
initiation and support of ectopic (epithelial and stromal) tissue growth causing endometriosis. 
Immunosuppressive MSC2 is induced by the inflammatory environment created by retrograde 
menstruation back into the pelvic cavity (e.g. IFN-γ, TNF-α), which then induces recruited 
monocytes to become M2 macrophages. MSC2 and M2 macrophages cause the levels of IDO1, 
PGE2, TGF-β1, IL-10, and M-CSF to increase in the pelvic cavity, inducing TH2 responses 
including Tregs, and decreased functions of DC, NK cells and CD8 T cells. The net effect is 
promotion of ectopic tissue growth and development of endometriosis.  
MSC2: mesenchymal stromal cell type 2, TH2: T helper 2 cell, Treg: T regulatory cell, CD8 T 
cell: cytotoxic CD8 T cell, DC: dendritic cell, NK cell: natural killer cell, IFN-γ: interferon-
gamma, TNF-α: tumour necrosis factor-alpha, IDO1: indoleamine 2,3-dioxygenase 1, PGE2: 
prostaglandin E2, TGF-β1: transforming growth factor-beta 1, IL-10: interleukin-10, M-CSF: 
macrophage-colony stimulating factor. 
Finally, one could speculate that redirecting MSC2 in ectopic lesions towards MSC1 may be 
useful in endometriosis by promoting M1 macrophages, and hence TH1 responses. The M1 
macrophages could favor increased responses of downstream immune cells such as DC to 
promote antigen presentation, and cytotoxic NK and T cell functions to help clear the ectopic 
lesions in the peritoneal cavity, and simultaneously inhibit the immunosuppressive functions 
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of Tregs. Accordingly, clearing the peritoneal cavity from the fibrotic ectopic lesions, and the 
associated inflammation may help address the two major symptoms of endometriosis; 
infertility and chronic pelvic pain, and potentially treat this enigmatic disease.  
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2 HYPOTHESIS 
In this PhD project it was hypothesized that MSC derived from endometriotic ovarian cysts 
could be involved in the reduced immunosurveillance of ectopic endometrial tissue in the 
pelvic cavity through their immunosuppressive effects on macrophages and NK cells. 
Moreover, if autologous MSC are involved in the pathology, then it was hypothesized that the 
immunomodulatory capabilities of allogeneic MSC could be a potential therapeutic strategy to 
target the inflammatory component of endometriosis.  
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3 AIMS 
Although MSC have been suggested to be involved in the pathogenesis of endometriosis, 
their role in its pathogenesis is still not completely clear. Moreover, the therapies that are 
currently available are not effective, and are associated with a high recurrence rate of ectopic 
lesions and symptoms. Therefore, the overall aim of this thesis was to understand the role of 
MSC in the pathogenesis of endometriosis, and to examine whether allogeneic MSC could 
potentially be a therapy for endometriosis. To fulfill these aims, the following studies were 
conducted with the following specific aims:  
 
Study 1. To examine if ESCcyst and ESCendo differ in terms of their phenotype and 
immunomodulatory effects in vitro. 
 
Study 2. To examine the direct effects of allogenic adipose tissue-derived MSC (Ad-MSC) 
on ESCcyst and ESCendo in vitro. 
 
Study 3. To examine the interactions of allogeneic NK cells and ESCcyst and ESCendo in 
vitro. 
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4 MATERIALS AND METHODS 
The papers and manuscript included in this thesis contain detailed descriptions of the materials, 
methods, and statistics used. The publications have the exact manufacturers of reagents, 
consumables, and hardware so please refer to them. Therefore, this section will briefly discuss 
the materials and methods that were utilized in the studies. 
4.1 ETHICAL CONSIDERATIONS  
Ethical approval for all the studies presented in this thesis was obtained from the Regional 
ethics committee in Stockholm, Sweden. This includes: isolation of stromal cells (2013/1094-
31/2) from endometriotic ovarian cysts and the endometrium of women with endometriosis, 
and isolation of stromal cells from adipose tissue biopsies obtained from women that underwent 
planned caesarian sections (2017/1017-32). All patients gave oral and signed informed consent, 
and the studies were in accordance with the Declaration of Helsinki.  
4.2 MATERIALS FOR STUDIES  
4.2.1 Stromal cells from women with endometriosis and healthy pregnant 
women 
The methods utilized to isolate the stromal cells from women with endometriosis (n=4) that 
were used for Studies 1, 2, and 3, and from healthy pregnant women (n=2) that were used for 
Study 2 are similar to those used previously by various groups (107, 133, 150, 151), which is 
why we utilized them. Biopsies of endometriotic ovarian cyst tissues (for ESCcyst) and eutopic 
endometrial tissues (for ESCendo), and adipose tissues (for allogeneic Ad-MSC) from healthy 
pregnant women undergoing elective caesarian sections were digested using collagenase type 
I and II, respectively. Allogeneic Ad-MSC were used because autologous MSC from women 
with endometriosis were founded to be altered by the pathology in Study 1. Following 
digestion we filtered out contaminating cells including epithelial cells and undigested tissue 
using 100 and 40 µm cell strainers. Eventually, the cells were resuspended in complete growth 
medium containing Dulbecco modified essential medium low glucose + 10% MSC certified 
fetal calf serum (FCS) + 1% antibiotic and antimycotic and cultured at 4000 cells/cm2 in tissue 
culture flasks at 37 °C with 5% CO2. When the cells reached 70-90% confluency, they were 
trypsinized using 0.05% trypsin/EDTA, and cultured as described above and used for the 
various experiments in Studies 1, 2, and 3 from passage three until passage seven. This method 
of isolation takes advantage of the adherent properties of MSC (152); the idea is that the 
primary stromal cells eventually outgrow all the other contaminating cells by passage three. 
The MSC were confirmed using the standard procedures of colony forming units- fibroblasts 
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(CFU-F), flow cytometry, and differentiation into adipocytes and osteoblasts, as described 
previously (106), which are important methods to verify MSC characteristics (98). However, 
there are limitations associated with these methods of isolation, which include potential 
changes to the phenotypic and functional properties of the MSC following digestion by 
collagenase and due to culture on plastic surfaces, the potential contamination by a small 
number of other types of cells, and the heterogeneous nature of the MSC populations used in 
the experiments (153, 154). Due to such limitations, there has been development of other MSC 
isolation methods; direct isolation of MSC from cell suspensions obtained following digestion 
of tissues biopsies using specific MSC markers using fluorescence activated cell sorters for 
immediate use as native MSC in experiments or following culture on plastic surfaces (155, 
156), direct isolation of MSC from cell suspensions obtained following digestion of tissue 
biopsies using specific MSC markers using magnetic beads for immediate use as native MSC 
in experiments or following culture on plastic surfaces (157), and harvesting of MSC following 
their migration from the cut ends of tissue explants cultured on plastic surfaces (96). The 
utilization of primary MSC from women with endometriosis and healthy pregnant women is 
an advantage, because these cells are minimally altered when cultured in vitro, and closely 
resemble the original cells found in vivo, compared to the use of the commonly used 
endometriosis 12Z (158) and stromal 22B (158) cell lines that are genetically altered (159). 
However, compared to cell lines, primary cells do not proliferate much in vitro, making their 
use in experiments more limiting (159). 
4.2.2 Monocytes from healthy female volunteers 
Monocytes that were used in Study 1 were isolated from buffy coats donated by healthy female 
volunteers (n=3) using magnetic beads through a process termed negative selection. 
Essentially, all the non-monocytes are magnetically labelled with a cocktail of biotin-
conjugated antibodies against CD3, CD7, CD16, CD19, CD56, CD123, and Glyocophorin A, 
and antibiotin microbeads, which are then removed from the cell suspensions leaving the 
monocytes for later use in experiments. The monocytes were cultured in complete growth 
medium containing Roswell Park Memorial Institute 1640 growth medium + 10% FCS + 1% 
L-glutamine + 1% penicillin and streptomycin. An advantage of this method is that the 
monocytes are untouched and hence are not activated, and a disadvantage of this method is the 
phenotypes and functions of the monocytes may have been altered by culture on the plastic 
surfaces. However, compared to an older method that isolated monocytes through a process of 
adherence following several hours of culture of PBMCs, this method allows a more pure (≥ 
95% pure) population of monocytes to be isolated in a shorter period of time (160). 
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4.2.3 NK cells from healthy female volunteers 
Natural killer (NK) cells that were used in Study 3 were isolated from buffy coats donated by 
healthy female volunteers (n=26) using magnetic beads through a process termed negative 
selection. Essentially, all the non-NK cells such as T cells, B cells, stem cells, dendritic cells, 
monocytes, granulocytes, and erythroid cells are indirectly magnetically labelled with a 
cocktail of biotin-conjugated antibodies and a cocktail of microbeads, then they are removed 
from the cell suspensions leaving the NK cells for later use in experiments. The NK cells were 
cultured in complete growth medium containing Stem Cell Growth Medium + 20% FCS + 500 
U/mL IL-2. An advantage of this method is that the NK cells are untouched and hence are not 
activated, allowing a more pure (≥ 95% pure) population of NK cells to be isolated in a short 
period of time compared to an older method of NK cell isolation (161), and a disadvantage of 
this method is that the phenotypes and functions of the NK cells may have been altered by 
culture on the plastic surfaces.  
4.2.4 Conditioned medium from MSC 
The method used to collect CM from MSC for Studies 1, 2, and 3 is similar to what has been 
previously used by various groups (24, 162, 163). Briefly, MSC are grown up to 70-90% 
confluency, then the growth medium is removed, and the cells are washed twice with phosphate 
buffered saline. Then fresh growth medium is added. Following three days of culture, the 
growth medium is obtained from the tissue culture flasks, centrifuged at 500xg for 10 min, 
filtered using a 0.2 µm filter to remove contaminating cellular debris, and then stored at -80 °C 
for later use in experiments. For the CM experiments in Study 2, a similar procedure was used 
to collect CM from Ad-MSC/ESCcyst, and Ad-MSC/ESCendo co-cultures from the in vitro cell 
culture experiments. Obviously, the advantage of using CM is that experiments are simple to 
prepare compared to experiments employing transwells or direct co-culture between cells, and 
although they are not entirely representative of the in vivo microenvironment, they still offer a 
snapshot of what may occur in vivo.  
4.2.5 Other cells and cell lines used 
Human umbilical vein endothelial cells (HUVEC) were kindly provided by Dr. Nina Heldring 
(Karolinska Institutet) and used in Study 2. They were isolated (n=2) as previously described 
(164) and grown on 0.1% gelatin coated surfaces in complete HUVEC growth medium 
containing human endothelial serum-free basal medium + 10% FCS + 1% penicillin and 
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The solitary cell line used in this PhD project was in Study 3, which was the K562 cell line, 
chronic myelogenous leukemia cells that were used as target cells in the 51Cr release assay (see 
below). This cell line is commonly used in this assay because they are suspension cells that are 
easy to monitor in vitro, and their genetic makeup (lack of HLA class I) makes them sensitive 
to killing by NK cells (165).  
4.3 METHODS FOR STUDIES 
4.3.1 Cell culture methods 
This PhD project utilized the commonly used method of in vitro cell culture for Studies 1, 2, 
and 3. We did not use in vivo animal models for any of the studies, because we first wanted to 
examine the MSC in vitro before examining them further in vivo to validate the in vitro 
findings. Nevertheless, the most relevant in vivo animal model for endometriosis is primates 
such as Baboons (166), and not the commonly used rodent (28, 106, 167) and rabbit models 
(168), because they have a menstrual cycle similar to female humans. The advantages of in 
vitro cell culture studies is that they are less expensive, take a shorter time and hence can be 
carried out more often than in vivo studies, since there is access to a sufficient amount of cells 
that are easier to maintain than animal models (169). In contrast, the disadvantage of in vitro 
cell culture is that they don’t represent the in vivo microenvironment as well as in vivo animal 
models (169). Also, it must be mentioned that we used 2D cell culture, which is easier to carry 
out than 3D cell culture, however, they are less representative of the in vivo microenvironment 
(159). Furthermore, we utilized various cell culture methods such as cell proliferation, 
apoptosis, adhesion, angiogenesis, migration, and invasion assays. We also used various 
systems in in vitro cell culture including CM, transwell, and direct co-culture systems. The 
following sections will discuss the various assays and systems we used in in vitro cell culture 
in this PhD project.  
4.3.1.1 Cell proliferation assays 
In Study 2, following the in vitro cell cultures employed, several cell proliferation assays were 
used including the manual cell count, carboxyfluorescein succinimidyl ester (CFSE), and MTT 
(d-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays to examine the effects 
of Ad-MSC on the proliferation of ESCcyst and ESCendo. The purpose of using several cell 
proliferation assays was to validate the findings through more than one method. The manual 
cell count assay is a routinely used method in in vitro cell culture, where in this case the cells 
are stained with a dye like eosin. Eosin only stains dead cells red due to their disrupted cell 
membrane, while viable cells remain colorless under the light microscope, giving information 
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on cell number increases and viability. The advantage is it is a routine simple method, however, 
since it is prone to human error, we then employed the CFSE and the MTT assays. The CFSE 
and MTT assays have been previously used by others to measure cell proliferation (170, 171). 
Briefly, for the CFSE assay, the CFSE stained ESCcyst and ESCendo were assayed on a flow 
cytometer following the experiments to measure their level of expression or median 
fluorescence intensity (MFI) of the CFSE dye; essentially the CFSE dye is diluted when cells 
proliferate leading to a reduced fluorescence and hence MFI with time, the greater the cell 
proliferation then the lower MFI (172). The CFSE assay is easy to use to quickly label target 
cells, the dye is also retained for a while in cells, and it is non-toxic with minimal effects on the 
proliferation ability of the stained cells (173). In addition, it is a more quantitative method than 
the other assays we employed for cell proliferation since it uses flow cytometry. However, a 
limitation is that it is prone to bleaching and may lead to irreproducibility, and therefore care 
must be taken to avoid exposure to light (173). However, CFSE is a common method used to 
measure cellular proliferation, which is why it was utilized (173). 
Briefly, for the colorimetric MTT assay, ESCcyst and ESCendo were stained with the MTT dye 
following the experiments to measure their optical density using a spectrophotometer. 
Essentially, the MTT dye is converted into purple formazan crystals that are then solubilized 
using DMSO in viable proliferating cells, hence giving information regarding cell number and 
proliferation (174). This assay is not expensive, and it is a simple and quick alternative to derive 
cell proliferation data before validation using more expensive methods (174). Compared to 
fluorescent methods such as the CFSE assay, this assay is less sensitive, which is why we also 
used the CFSE assay (174). Moreover, the number of washes and steps in the procedure has 
led to the development of assays such has the MTS assay that does not require any washing 
steps (175). Nevertheless, the MTT assay is a commonly used assay that provides valuable 
information on cell proliferation (176).  
4.3.1.2 Cell apoptosis assay 
In Study 2, the annexin V assay was utilized to examine the apoptosis of ESCcyst and ESCendo 
following their in vitro cell culture with Ad-MSC. Briefly, following the experiments ESCcyst 
and ESCendo were stained with the annexin V antibody and 7-AAD. Annexin V binds to 
phosphatidyl serine that becomes exposed on a cell’s surface during apoptosis, and 7-AAD 
binds to intracellular DNA in membrane compromised cells undergoing necrotic death (177). 
Then the cells are assayed on a flow cytometer and scatterplots are created with annexin V 
versus 7-AAD giving data on the percentage of cells undergoing early apoptosis (only annexin 
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positive), late apoptosis (annexin and 7-AAD positive), or necrosis (only 7-AAD positive) 
(178). The advantage of this assay is that it gives information on both cell viability and the 
various types of cell death. In addition, it gives more quantitative data than methods such as 
the comet assay, since it makes use of flow cytometry (179). The disadvantages of this assay 
is that only live cells can be used during staining compared to the terminal deoxy transferase-
mediated dUTP nick end labelling (TUNEL) assay that can be done with fixed cells, and unlike 
the TUNEL assay it does not give information regarding the phase of the cell cycle apoptosis 
is occurring (179). However, the annexin V assay has been previously used in the field of 
endometriosis to measure apoptosis, which is why we utilized it (180, 181). 
4.3.1.3 Cell adhesion assay 
 
In Study 2, the fibronectin adhesion assay was utilized to examine the adhesion of ESCcyst and 
ESCendo following their in vitro cell culture with Ad-MSC. Briefly, following the experiments 
ESCcyst and ESCendo were incubated on fibronectin coated wells of 96 well plates for two hours. 
Then the cells were washed so that only the adherent cells were measured in the MTT assay as 
described above. Fibronectin is an extracellular matrix protein normally found in the pelvic 
cavity in women with endometriosis, which is why we used it (182). As stated above, the MTT 
assay is a cheap, easy and quick method to employ, however, compared to fluorescent methods 
it is less sensitive (174). Nonetheless, this assay is similar to what has been previously used in 
the field of endometriosis to measure cell adhesion (182, 183). 
4.3.1.4 Tube formation assay 
In Study 2, the tube formation assay was utilized to examine the tube formation of HUVEC on 
matrigel coated wells in 96 well plates while they were being cultured in the CM derived from 
co-cultures of Ad-MSC/ESCcyst and Ad-MSC/ESCendo. This method is an in vitro model of 
angiogenesis that has been established previously (184). Briefly, HUVEC were allowed to 
grow on matrigel coated wells in the aforementioned CM for 17-18 hours, then images were 
taken of the tubes the HUVEC formed at 4x magnification that displayed the whole well, and 
the number of tubes formed per well were quantified using the angiogenesis analyzer plugin 
on ImageJ as previously described (185). The limitations of this assay is that there may be a 
lack of consistent lumen formation in the rings, which may affect reproducibility of 
experiments, and its correlation to the in vivo situation is unclear (186). However, an advantage 
of this assay is that it is a good representation of all the processes that endothelial cells must 
undergo in vivo during angiogenesis in order to form rings, such as migration, proliferation, 
 
27 
 
positive), late apoptosis (annexin and 7-AAD positive), or necrosis (only 7-AAD positive) 
(178). The advantage of this assay is that it gives information on both cell viability and the 
various types of cell death. In addition, it gives more quantitative data than methods such as 
the comet assay, since it makes use of flow cytometry (179). The disadvantages of this assay 
is that only live cells can be used during staining compared to the terminal deoxy transferase-
mediated dUTP nick end labelling (TUNEL) assay that can be done with fixed cells, and unlike 
the TUNEL assay it does not give information regarding the phase of the cell cycle apoptosis 
is occurring (179). However, the annexin V assay has been previously used in the field of 
endometriosis to measure apoptosis, which is why we utilized it (180, 181). 
4.3.1.3 Cell adhesion assay 
 
In Study 2, the fibronectin adhesion assay was utilized to examine the adhesion of ESCcyst and 
ESCendo following their in vitro cell culture with Ad-MSC. Briefly, following the experiments 
ESCcyst and ESCendo were incubated on fibronectin coated wells of 96 well plates for two hours. 
Then the cells were washed so that only the adherent cells were measured in the MTT assay as 
described above. Fibronectin is an extracellular matrix protein normally found in the pelvic 
cavity in women with endometriosis, which is why we used it (182). As stated above, the MTT 
assay is a cheap, easy and quick method to employ, however, compared to fluorescent methods 
it is less sensitive (174). Nonetheless, this assay is similar to what has been previously used in 
the field of endometriosis to measure cell adhesion (182, 183). 
4.3.1.4 Tube formation assay 
In Study 2, the tube formation assay was utilized to examine the tube formation of HUVEC on 
matrigel coated wells in 96 well plates while they were being cultured in the CM derived from 
co-cultures of Ad-MSC/ESCcyst and Ad-MSC/ESCendo. This method is an in vitro model of 
angiogenesis that has been established previously (184). Briefly, HUVEC were allowed to 
grow on matrigel coated wells in the aforementioned CM for 17-18 hours, then images were 
taken of the tubes the HUVEC formed at 4x magnification that displayed the whole well, and 
the number of tubes formed per well were quantified using the angiogenesis analyzer plugin 
on ImageJ as previously described (185). The limitations of this assay is that there may be a 
lack of consistent lumen formation in the rings, which may affect reproducibility of 
experiments, and its correlation to the in vivo situation is unclear (186). However, an advantage 
of this assay is that it is a good representation of all the processes that endothelial cells must 
undergo in vivo during angiogenesis in order to form rings, such as migration, proliferation, 
41
 28 
 
and matrix degradation (186). This procedure is similar to what has been used previously in 
the field of endometriosis to measure tube formation (187, 188). 
4.3.1.5 Cell migration and invasion assays 
In Study 2, migration and invasion transwell assays were utilized to examine the migration and 
invasion of ESCcyst and ESCendo, respectively, following their in vitro cell culture with Ad-
MSC. These assays have been previously used in the field of endometriosis to measure 
migration and invasion of ESC (189, 190). Briefly, following culture with Ad-MSC, ESCcyst 
and ESCendo were harvested and seeded on 8 µm pore transwell inserts, with FBS placed in the 
bottom to allow a chemotactic gradient to induce migration or invasion of the ESC through the 
pores and then to attach to the other side of the inserts. For the invasion assay, matrigel was 
used to coat the upper surface of the transwell inserts, so that the ESC also have to degrade and 
invade the extracellular matrix before migrating to the bottom side of the inserts. The non-
migrated or non-invaded cells were removed using cotton swabs, then the migrated or invaded 
cells were stained with eosin. Finally, images were taken of the inserts in five randomly chosen 
areas at 10x magnification, and the number of cells migrated or invaded were counted using 
ImageJ. A disadvantage of these assays is that they are endpoint assays that do not provide 
much information about the actual processes involved in migration and invasion (191). 
However, the availability of different inserts and sizes, and the ease at which the experimental 
setup is prepared are advantages (191). 
4.3.1.6 Conditioned medium, transwell and direct co-culture systems 
In this PhD project, the CM, transwell, and direct co-culture systems were employed during in 
vitro cell culture; Figure 2 shows an example of the systems in Study 2. These systems were 
carried out, because they are normally used in the field of in vitro cell culture, and have been 
used previously by others (24, 60, 144). Each of the systems provides a different snapshot of 
the in vivo microenvironment, so that together they help to form a more complete picture of 
what might potentially occur. In the CM system the factors that are present are examined for 
their effect on the target cells. In contrast, in the transwell system the target cells in the bottom 
wells influence the type of factors that are secreted by the cells in the upper inserts, so it is 
mimicking paracrine signaling. Finally, in the direct co-culture system both cell types are 
cultured together in the same well to examine their effects on each other in terms of a certain 
parameter, for example in Study 2, we examined the effect of culture of Ad-MSC with ESC 
on the apoptosis and survival of ESC. 
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Figure 2. Showing the various systems that were employed during in vitro cell culture in Study 
2. 
An illustration showing the various systems that were employed during in vitro cell culture in 
Study 2. The CM system contained already secreted factors from Ad-MSC, which were 
examined for their effect on ESC. Meanwhile, the transwell system had ESC in the bottom wells 
that controlled the type of factors that were secreted by Ad-MSC in the upper inserts. Finally, 
in the direct co-culture system both Ad-MSC and ESC were cultured together in the same well 
to examine their effects on each other in terms of a certain parameter, for example, apoptosis 
and survival of ESC. 
4.3.2 Flow cytometry  
Flow cytometry is a commonly used method to carry out phenotypical and functional studies 
involving cells of interest (192). In this PhD project we used this method in Studies 1, 2, and 
3. The main use of this method was to characterize various cell types in the studies such as 
MSC, macrophages, and NK cells. Flow cytometry can be used to stain cells extracellularly on 
the cell surface or intracellularly within the cells (192), with both techniques being used in this 
PhD project. For the former, cells are incubated with the appropriate antibodies targeting 
certain antigens on the cell surface (192). However, for the latter the cells need to be fixed and 
permeabilized in order to prepare them for incubation with antibodies that will enter and stain 
antigens within the cells (192). Eventually, the cell suspensions are assayed on a flow 
cytometer, and parameters such as side scatter (cell granularity) and forward scatter (cell size) 
on scatterplots, are used to locate and further analyze certain cell populations for the percentage 
of cells that express a certain antigen using histograms and scatterplots (192). In addition, the 
intensity of expression of a certain antigen on the cells of a population of interest is measured 
via a parameter termed the MFI (192).  
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The advantages of flow cytometry is that it is quiet easy to employ, can be carried out quite 
fast, and is much more quantitative compared to other protein measurement methods such as 
western blotting, immunofluorescence microscopy, immunocytochemistry, and 
immunohistochemistry, which require several days to carry out. However, it certainly would 
be more complete to have quantitative data regarding a protein using flow cytometry, and 
fluorescence or colorimetric imaging using immunofluorescence microscopy or 
immunohistochemistry of the same protein in the target tissue. Moreover, the quantitative 
nature of the method makes it possible to have access to a multitude of parameters that can be 
used to understand the cell populations of interest due to the potential use of various antibodies 
conjugated with various fluorophores against various cellular antigens (192). A disadvantage 
of this method is that surface molecules on cells may be cleaved off following trypsinization, 
and the cells must be in suspension so information regarding tissue architecture or cell-cell 
interactions of adherent cells is lost (193). Moreover, it can be costly due to the price of 
antibodies, and the fact that the actual flow cytometers are expensive to purchase and to 
maintain. Also, sometimes a large number of cells are required for analysis, which may not be 
possible to obtain if slowly growing primary cells are used. The fluorophores that are 
conjugated to the antibodies are used to quantify the various antigens of interest via their 
emission of fluorescence of various wavelengths, however, there can be overlap between the 
emission wavelengths of different fluorophores, which makes them difficult to distinguish from 
each other especially when a large number of fluorophores are used in an experiment, even if 
strict compensation and fluorescence minus one controls are employed to remove fluorescence 
spillage (193). Therefore, recently there has been development of mass cytometry that 
overcomes the spectral overlap associated with flow cytometry, by utilizing probes linked to 
unique stable, heavy-metal isotopes that can be distinguished with high accuracy (194). 
Nevertheless, flow cytometry is still a widely used method that offers the possibility of 
extracting a large amount of data from experiments, hence why it was used in this PhD project.  
4.3.3 Quantitative polymerase chain reaction  
Quantitative polymerase chain reaction (qPCR) was used in Study 1, because it is a common 
method to quantify gene expression, and because only several genes were examined. Briefly, 
RNA was extracted from the MSC, then it was reverse transcribed into cDNA, which was 
eventually quantified for various genes using customized primers. The advantages of this 
method compared to conventional PCR and the older method of Northern blot is that it is highly 
sensitive since it allows the detection of low-copy targets, it has a wide dynamic range, it is 
more accurate, is more quick to carry out due to less steps, is less expensive, is highly 
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quantitative as absolute copy numbers can be determined, and there is elimination of cross-
contamination due to the closed-tube format (195, 196). However, more recent methods such 
as digital PCR, microarrays, serial analysis of gene expression, and RNA sequencing have the 
ability to examine the expression of many genes (was not our aim) so they are less time 
consuming, are highly reproducible, and require less starting amounts of RNA compared to 
qPCR (197). Moreover, we utilized SYBR Green as a probe, which has disadvantages 
compared to other probes like TaqMan, of being less accurate and specific, and it is not possible 
to do multiplex PCR or to determine the expression of several genes simultaneously (198). 
However, compared to the TaqMan method, SYBR Green is less expensive, provides relative 
and not absolute quantitation (what we wanted), and it is easier to use, which is why we utilized 
it in the PhD project (198).  
4.3.4 Chromium 51 release assay 
The 51Cr release assay is a standard assay that has been widely utilized in the study of NK cell 
cytotoxicity, hence why we used it in Study 3 (199). Briefly, we labelled the target cells in 
Study 3 with 51Cr for 1 hour which were the K562 cell line or the ESC, then we cultured them 
with the effector NK cells in V-bottom 96 well plates for four hours. Then the supernatants that 
contained the 51Cr released following the lysis of either the K562 cell line or the ESC were 
collected and assayed on an automated gamma counter. Negative control wells containing only 
complete growth medium for spontaneous release of 51Cr, and positive control wells containing 
2M hydrochloric acid for maximum lysis of 51Cr labelled target cells and maximum release of 
51Cr were included. Finally, the counts per minute were used to calculate the percentage killing 
of the target cells carried out by the effector NK cells using the standard formula (199): 
% cytotoxicity = [(experimental - spontaneous release)/(maximum release - spontaneous 
release) x 100]  
The advantages of this assay is that as previously mentioned, it uses the K562 cell line that is 
easy to maintain, and that is sensitive to NK cell killing due to the lack of expression of HLA-
I (165). Moreover, the assay only requires a small number of cells. However, the disadvantages 
of this assay are the costs and the handling of radioactivity involved, as well as the fact that 
only dead cells are measured, and there is no information on both live and dead cells or cells 
undergoing various stages of cell death (200). Various other assays have been developed to 
overcome the disadvantages such as the real-time digital bio-imaging cytotoxicity assay (200), 
a bioluminescence imaging assay (201), and the antibody-dependent cell-mediated cytotoxicity 
and complement dependent cytotoxicity assays (202), among others. However, the 51Cr release 
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assay is still widely used, and remains the most sensitive assay to examine NK cell cytotoxicity 
(200), hence why we used it in this PhD project. We also carried out the degranulation assay 
in Study 3, which examines NK cell cytotoxicity, but by measuring the expression of the 
degranulation marker CD107a in NK cells (203). Degranulation is a process where there is a 
release of granules from NK cells that are involved in NK cell killing of target cells (203).  
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5 RESULTS AND DISCUSSION 
The papers and the manuscript included in this thesis contain the detailed description and 
discussion of the results. Therefore, this section will only briefly describe and discuss the 
results of the studies carried out in this PhD project.  
5.1 STUDY 1 
MSC have been found in the pelvic cavity of women with endometriosis (106), however, it is 
not completely known what the involvement of MSC may be in endometriosis. Therefore, we 
examined the phenotype and function of MSC in women with endometriosis to gain more 
insight regarding their potential role in endometriosis.  
Initially, we confirmed that both ESCcyst and ESCendo were MSC following the use of the 
commonly used standard assays of CFU-F, flow cytometry for MSC markers, and osteoblast 
and adipocyte differentiation, as shown before (106). Then ESCcyst and ESCendo were compared 
phenotypically and functionally. Phenotypically, we examined the expression of IDO1, COX2, 
and HO-1, which are immunosuppressive enzymes that have been suggested to be highly 
expressed by immunosuppressive MSC2 (103). Moreover, MSC2 has been suggested to 
express lower levels of immunostimulatory molecules such as CXCL12, so we also examined 
its expression in the ESC (103). ESCcyst expressed IDO1, COX2, and HO-1 significantly more 
than ESCendo using both qPCR for gene expression, and flow cytometry for protein expression. 
These results are similar to some of the studies carried out previously (112, 113), however, 
some of the other studies (110, 150) have had conflicting results to ours. In addition, sometimes 
the comparisons have been made to ESCendohv, however, these control cells may introduce 
individual to individual variations in terms of the immunological microenvironment and 
endocrine factors (11, 108). Also, in some cases it was not clear if the ectopic stromal cells 
were from peritoneal endometriotic tissue, endometriotic ovarian cysts, or deep infiltrating 
endometriosis tissue, which are different types of endometriosis lesions (108). Moreover, 
herein we did not stimulate our ESC with immune cells or cytokines, in order to reflect the in 
vivo microenvironment more closely, in contrast to a previous study (11). 
Interestingly, ESCcyst expressed significantly higher and lower levels of the protein and gene 
of CXCL12 compared to ESCendo, respectively. This finding is similar to a study by another 
group (204), but they stimulated their cells with estrogen or progesterone, and unlike our study 
it does not reflect the in vivo microenvironment closely. The discrepancy of the protein and 
gene results may be due to posttranscriptional and posttranslational processes, since it is known 
that there are weak correlations between mRNA and protein expression (205). However, 
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proteins are more important in cellular function (205), and so therefore ESCcyst may also be 
more immunostimulatory than ESCendo: this may due to their dynamic responses to fluctuations 
in the levels of pathological inflammation in the pelvic cavity.  
IDO1, COX2 via secretion of PGE2, and HO-1 have been suggested to induce 
immunosuppressive M2 macrophages. Interestingly, M2 macrophages are predominantly 
found in ectopic lesions in women with endometriosis, however, the mechanisms of their 
induction are not known (18, 28).  Therefore, we carried out a functional study, where we found 
that ESCcyst induced more monocytes to differentiate into M2 macrophages than ESCcyst; 
ESCcyst treated monocytes expressed CD14 and CD163 more significantly than ESCendo treated 
monocytes, and appeared to be more spindle shaped when they differentiated into 
macrophages. Accordingly, immunosuppressive ectopic MSC may be inducing 
immunosuppressive M2 macrophages in the pelvic cavity in endometriosis. Previously, several 
differently designed studies have suggested that M2 macrophages are induced in endometriosis 
due to ESC (19, 30). However, as mentioned earlier we believe the use of ESCendohv as control 
cells is not appropriate, and it is important to know the type of endometriosis lesions from 
which the ectopic stromal cells are isolated. Moreover, we compared the effects of ESCcyst and 
ESCendo on unstimulated human primary monocytes, and to our knowledge this is the first time 
that this has been performed.  
The data shows that ESCcyst is more immunosuppressive than ESCendo both phenotypically and 
functionally. The pelvic cavity in women with endometriosis displays high levels of 
inflammation (206), and MSC are known to respond to their immediate microenvironment to 
attempt to maintain homeostasis (103). Therefore, the inflamed pelvic cavity may induce 
ESCcyst to become more immunosuppressive to allow them to reduce inflammation and 
promote tissue homeostasis. It is well known that the pelvic cavity in women of endometriosis 
has reduced immunosurveillance leading to immune escape of ectopic lesions, but it is not 
currently known why this occurs (35). However, it may be associated with the 
immunosuppressive effects of ESCcyst, which may be mediated partly via their promotion of 
recruited monocytes into immunosuppressive M2 macrophages. Finally, the M2 macrophages 
may directly (18) and indirectly (207) through their immunosuppressive effects on other 
immune cells, support the growth of ectopic lesions in endometriosis. 
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5.2 STUDY 2 
Endometriosis is known to be an inflammatory disease (208), and MSC are known to be 
immunosuppressive; so MSC may be potentially useful as a therapy for endometriosis (209). 
Moreover, based on the findings in Study 1, it seemed that autologous MSC are altered by the 
pathology of endometriosis. Therefore, in this study we examined the effects of allogeneic 
MSC on ESC in vitro in various cell co-culture assays to examine if MSC could potentially be 
a therapy for endometriosis. Specifically, cell proliferation, apoptosis, adhesion, migration, 
invasion, and tube formation assays were carried out to examine the effects of Ad-MSC on 
ESCcyst and ESCendo in vitro.  
Initially, the effects of Ad-MSC on the proliferation of ESCcyst and ESCendo was carried out. 
The three methods of manual cell count, CFSE, and MTT assays were used in order to validate 
the findings through the use of more than one method. The CM system induced cell 
proliferation of ESCcyst and ESCendo significantly compared to untreated controls, while the 
transwell system had no effect on cell proliferation, using all three methods. Some of these 
findings were similar to a previous study (129), and conflicting with other studies (210, 211), 
which may be due to the use of different sources of MSC, as has been previously described 
(212). There is a paracrine effect in the transwell system that is absent in the CM system, which 
may lead ESCcyst and ESCendo to secrete factors that may inhibit the Ad-MSC in the top inserts 
from secreting proliferation-promoting factors (213). Meanwhile, the direct co-culture system 
had in some cases no effect or in some cases caused a decrease in the proliferation of ESCcyst 
and ESCendo. The decrease in cell proliferation may be due to the contacted mediated inhibitory 
effects by Ad-MSC. 
It was found that the Ad-MSC promoted the survival and reduced the apoptosis of ESCcyst and 
ESCendo. These findings are similar to other studies (214-216) carried out in other cell types, 
and they differ from a study that used MSC from another source (211). Moreover, the findings 
suggest that MSC present in the pelvic cavity in women with endometriosis could potentially 
promote the survival and reduce apoptosis of stromal cells.  
The transwell system caused a significant increase in the adhesion of ESCendo, but had no effect 
on ESCcyst. Meanwhile, the CM system caused a significant decrease in the adhesion of ESCcyst, 
but it had no effect on the adhesion of ESCendo. These findings go in line with the cell 
proliferation data, since cells that divide rapidly are less likely to be adherent (217). In addition, 
the differences between the transwell and CM systems is due to a paracrine effect present in 
the former and absent in the latter. There have been no other previous studies that examined 
the effects of MSC on the adhesion of ESCcyst and ESCendo. 
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The CM collected from Ad-MSC/ESCcyst and Ad-MSC/ESCendo co-cultures significantly 
promoted the tube formation of HUVEC compared to untreated controls. There have been no 
similar previous studies conducted. Moreover, these findings are in corroboration with others 
who found that MSC have the ability to promote tube formation (218-220). 
The transwell system significantly increased the migration of ESCcyst but had no effect on 
ESCendo, and it had no effect on the invasion of either cell type, compared to the untreated 
controls. The CM system significantly reduced the migration and invasion of both cell types. 
This data is in accordance with the cell adhesion data, since migration and invasion require 
initial adhesion of cells (221). Also, the differences between the transwell and CM systems are 
due to the presence of a paracrine effect in the former. A similar study found conflicting data 
to ours (129), which could be explained by their different source of MSC. 
We in Study 1 and others (106) have found that MSC are recruited to ectopic lesion in women 
with endometriosis. Therefore, based on the findings in this study it seems that ectopic MSC 
may be involved in the promotion of cell proliferation, survival, and migration, as well as 
supporting endothelial cells in angiogenesis, to allow the direct growth of ectopic lesions. 
Finally, it must be remembered that these findings may not hold true for MSC from other 
sources, which should still be investigated as a potential therapy for endometriosis.  
5.3 STUDY 3 
As mentioned earlier, various immune cells such as NK cells are recruited to the pelvic cavity 
in women with endometriosis, however, their functions have been found to be reduced (16, 
17, 67). Although it is not completely known why there is immune inhibition in the pelvic 
cavity of women with endometriosis, in Study 1 we found that ESCcyst from women with 
endometriosis may be involved in part through their promotion of immunosuppressive M2 
macrophages. Therefore, herein we wanted to examine if ESCcyst also had similar inhibitory 
effects on the phenotype and function of allogeneic NK cells.  
 
NK cells were cultured in the CM of ESCcyst and ESCendo, and their cytotoxic function was 
examined. We found that there were no differences in NK cell cytotoxicity between ESCcyst 
and ESCendo using the 
51Cr release assay. Similarly, the phenotype of the NK cells treated with 
the CM of ESCcyst was similar to the NK cells treated with the CM of ESCendo, with no 
significant differences in the expression of activating, inhibitory, maturation or adhesion 
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markers. In addition, there were no significant differences in the NK cell degranulation marker 
CD107a, or in the expression of the proinflammatory cytokine IFN-γ from the NK cells. 
Furthermore, the percentage of NK cells expressing IFN-γ and CD107a was similar for both 
ESCcyst and ESCendo. Secreted factors may not have been present at a significant concentration 
in the CM of ESCcyst to have an evident effect on NK cell cytotoxicity since they may have 
been short-lived as many cytokines are (222). To the best of our knowledge, no previous studies 
comparing the CM of ESCcyst and ESCendo on the phenotype of NK cells have been carried out. 
However, there have been differently designed studies that have generally found that NK cell 
cytotoxicity is significantly inhibited in women with endometriosis compared to women 
without endometriosis, and this may be due to the effects of ESCendo compared to ESCendohv 
(16, 17, 132). However, a comparison to ESCendohv may not be appropriate since ESCendohv may 
introduce inter-individual variations in terms of the immunological microenvironment and 
endocrine factors. Furthermore, healthy eutopic endometrium serves as an inappropriate model 
for studying NK cell responses in endometriosis as ESC from ectopic endometriotic lesions 
may have significantly different behavior. 
Direct co-culture experiments with ESCcyst and ESCendo were carried out to examine their 
effects on NK cell cytotoxicity. The cytotoxicity of the NK cells in direct contact with ESCcyst 
was similar to NK cells that had been in direct contact with ESCendo. Therefore, the cell-cell 
interactions that occur in direct co-culture with ESCcyst compared to ESCendo may have a similar 
effect on NK cell cytotoxicity. According to the literature, there have been no similar previous 
studies comparing the effects of ESCcyst and ESCendo on the cytotoxicity of NK cells following 
direct co-culture. Instead, Oosterlynck et al. found that NK cells from the peripheral blood and 
peritoneal fluid of women with endometriosis have significantly reduced cytotoxicity against 
the K562 cell line and autologous ESCendo compared to NK cells from women without 
endometriosis (16, 17). Moreover, a similar study found that NK cells derived from the 
peripheral blood and peritoneal fluid of women with endometriosis had significantly reduced 
cytotoxicity against the K562 cell line compared to women without endometriosis (70). 
In contrast to the aforementioned NK cell cytotoxicity studies, we used NK cells from healthy 
female volunteers similar to a number of previous studies (60, 68, 133), which could explain 
the conflicting results. The use of NK cells from healthy female volunteers may not be 
appropriate for the investigation of NK cell immunomodulation in endometriosis. In 
conclusion, the reduced function of NK cells in the pelvic cavity in women with endometriosis 
may be due to other factors besides ESCcyst. However, NK cells from women with 
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conclusion, the reduced function of NK cells in the pelvic cavity in women with endometriosis 
may be due to other factors besides ESCcyst. However, NK cells from women with 
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endometriosis should be utilized in a future study in a similar co-culture system as ours, in 
order to confirm our findings. 
 
 
 
 
 
 
 
 
 
 
  
 
38 
 
endometriosis should be utilized in a future study in a similar co-culture system as ours, in 
order to confirm our findings. 
 
 
 
 
 
 
 
 
 
 
  
52
 39 
 
6 CONCLUSIONS AND FUTURE PERSPECTIVES  
6.1 CONCLUSIONS 
Several conclusions can be derived from this thesis: 
 Firstly, ESCcyst are more immunosuppressive than ESCendo. This could be due to ESCcyst 
responding to and opposing the high levels of inflammation in the pelvic cavity in order 
to attempt to maintain homeostasis. ESCcyst may be one of the mechanisms by which 
reduced immunosurveillance of ectopic endometrial tissue in the pelvic cavity occurs. 
They may be inducing recruited monocytes to differentiate into immunosuppressive 
M2 macrophages, which may directly support the growth of ectopic endometrial tissue, 
and inhibit the functions of other immune cells. The net effect might be an indirect 
promotion of the growth of ectopic endometrial tissue by ESCcyst.  
 Secondly, although MSC such as Ad-MSC are known to be immunosuppressive and 
endometriosis is an inflammatory disease, Ad-MSC should not be investigated further 
as a potential therapy for endometriosis, because they may directly support the growth 
of ectopic endometrial tissue and worsen the pathology. This also suggests that ectopic 
MSC such as ESCcyst may directly support the growth of ectopic endometrial tissue.  
 Thirdly, ESCcyst may not be involved in the known inhibition of NK cells in the pelvic 
cavity of women with endometriosis, suggesting that other factors may be involved. 
Taken together, ESCcyst may directly and indirectly through immunosuppressive M2 
macrophages support the growth of ectopic endometrial tissue in women with endometriosis. 
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6.2 FUTURE PERSPECTIVES  
The involvement of ESCcyst and immunosuppressive M2 macrophages in the pathogenesis of 
endometriosis could be further investigated by carrying out mechanistic studies to examine the 
mechanisms by which ESCcyst may be promoting immunosuppressive M2 macrophages. The 
subtypes of macrophages promoted could also be examined. Moreover, a similar co-culture 
system should be utilized in a future study but with NK cells from women with endometriosis 
to confirm our NK cell findings. To have a more complete story showing the effects of ESCcyst 
on the immune system in endometriosis, other immune cells such as DC, B cells, and T cells 
could also be investigated. 
Furthermore, although allogeneic Ad-MSC may directly support the growth of ectopic 
endometrial tissue in endometriosis, this may not be true for other sources of MSC, which 
should also be investigated. ESCcyst were examined in this thesis, however, MSC from other 
ectopic lesions such as early stage superficial peritoneal lesions and deep infiltrating 
endometriosis lesions should also be investigated as they may provide a different snapshot of 
the pathology.  
Finally, the findings of such in vitro studies could be further confirmed through the use of a 
relevant in vivo model such as the Baboon to conclude if MSC are in fact one of the major 
players in the pathology of endometriosis through their direct and indirect effects on the growth 
of ectopic endometrial tissue in the pelvic cavity. An improved understanding of the role of 
MSC in the pathology of endometriosis will help future research to devise ways to target them 
during the development of novel therapeutics. 
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